CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
CSPC Pharmaceutical
CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment
China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...
CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...
CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...
10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...
CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China
The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...
CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...
National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...
CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...
CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...